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Purpose: To use perfusion and magnetic resonance (MR) spectroscopy to compare the diffusion tensor imaging (DTI)-
defined invasive and noninvasive regions. Invasion of normal brain is a cardinal feature of glioblastomas (GBM) and a
major cause of treatment failure. DTI can identify invasive regions.
Materials and Methods: In all, 50 GBM patients were imaged preoperatively at 3T with anatomic sequences, DTI,
dynamic susceptibility perfusion MR (DSCI), and multivoxel spectroscopy. The DTI and DSCI data were coregistered to
the spectroscopy data and regions of interest (ROIs) were made in the invasive (determined by DTI), noninvasive regions,
and normal brain. Values of relative cerebral blood volume (rCBV), N-acetyl aspartate (NAA), myoinositol (mI), total chol-
ine (Cho), and glutamate1glutamine (Glx) normalized to creatine (Cr) and Cho/NAA were measured at each ROI.
Results: Invasive regions showed significant increases in rCBV, suggesting angiogenesis (invasive rCBV 1.64 [95% confi-
dence interval, CI: 1.5–1.76] vs. noninvasive 1.14 [1.09–1.18]; P< 0.001), Cho/Cr (invasive 0.42 [0.38–0.46] vs. noninvasive
0.35 [0.31–0.38]; P50.02) and Cho/NAA (invasive 0.54 [0.41–0.68] vs. noninvasive 0.37 [0.29–0.45]; P5< 0.03), sug-
gesting proliferation, and Glx/Cr (invasive 1.54 [1.27–1.82] vs. noninvasive 1.3 [1.13–1.47]; P5 0.028), suggesting gluta-
mate release; and a significantly reduced NAA/Cr (invasive 0.95 [0.85–1.05] vs. noninvasive 1.19 [1.06–1.31]; P50.008).
The mI/Cr was not different between the three ROIs (invasive 1.2 [0.99–1.41] vs. noninvasive 1.3 [1.14–1.46]; P5 0.68).
In the noninvasive regions, the values were not different from normal brain.
Conclusion: Combining DTI to identify the invasive region with perfusion and spectroscopy, we can identify changes in
invasive regions not seen in noninvasive regions.
J. MAGN. RESON. IMAGING 2015;00:000–000.
Despite our improved knowledge and understanding ofglioblastomas (GBM), they still carry a dismal progno-
sis. Survival can be improved by more aggressive surgical
resections1 and the combination of radiotherapy and chemo-
therapy, yet virtually all patients will die from progressive
disease. This disease progression is usually within the high
dose area of radiotherapy2–5 in an area of tumor invasion.
This invasive margin is a cardinal feature of GBM and is
one of the major causes of treatment failure.6 As the inva-
sive margin cannot be accurately identified with clinical,
anatomical imaging (T1-weighted, T2-weighted, and fluid-
attenuated inversion recovery [FLAIR] imaging),7,8 new
imaging methods are required to delineate it and to facili-
tate study of its biology.
Our understanding of what happens in the invasive
margin is less well developed than for the center of the
tumor. It is known that invading cells have a different phe-
notype and are more motile and less proliferative.9 The
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release of enzymes (such as metalloproteases) breaks down
the extracellular matrix and the release of glutamate (second-
ary to disruption of the glial matrix) destroys glia and neu-
ronal processes to provide space for tumor cells to
invade.10,11 As cell numbers increase the tumor cells become
hypoxic, providing an important trigger for changes both in
brain metabolism and angiogenesis that will lead to further
tumor cell invasion.12 Invasion is therefore a multistage,
multicellular process that cannot be completely studied
using a single method.
As invasion primarily involves white matter tracts,
imaging disruption of the architecture of the white matter
will be vital in identifying tumor invasion. Diffusion tensor
magnetic resonance imaging (DTI) is a technique sensitive
to the ordered diffusion of water along white matter tracts,
and it can detect subtle disruption. Studies have shown that
it can identify changes in white matter on the periphery of
an invasive GBM that are not seen in noninvasive metasta-
ses13,14 or meningiomas,15 suggesting that these changes in
the peritumoral area are due to invasion. Diffusion tensor
tissue signatures can split the tensor information into iso-
tropic diffusion (p: magnitude of diffusion) and anisotropic
diffusion (q: measure of the directionality of diffusion).16
This procedure can differentiate regions of pure tumor
(reduced q and increased p) from invaded white matter
(increased p alone)17 and is more sensitive than conventional
DTI measures such as fractional anisotropy (FA).8,18 Image-
guided biopsies of these regions have confirmed invasive
tumor with a high degree of accuracy in both high-grade
gliomas8 and low-grade gliomas.19 Follow-up studies have
shown that these regions predate the development of con-
trast enhancement at progression, and can predict the time
to tumor progression20 and its pattern.21,22 This provides a
valuable method of identifying the invasive tumor margin.
Dynamic susceptibility contrast perfusion imaging
(DSCI) provides information on the relative cerebral blood
volume (rCBV) that correlates with tumor vascularity23,24 and
cellular proliferation.25 Multivoxel MR spectroscopy (MRS),
or chemical shift imaging (CSI), reveals changes in tissue
metabolism within the invasive region. In this study we aimed
to understand the local environment of GBM by exploring
the perfusion and metabolic changes seen in the DTI-defined
invasive margin of GBMs and compare this to regions defined
as noninvasive by DTI. From our knowledge of the biology of
the invasive margin we would expect that multimodal imaging
methods will show that these DTI-defined invasive regions
will appear similar to the main tumor bulk.
Materials and Methods
Patients Recruited
Fifty patients (mean age 58.2, range 31.4–71.6 years; 33 males, 17
female) were recruited preoperatively for this prospective MRI
study. All patients had imaging appearances of a GBM and histo-
logical confirmation was subsequently obtained. All patients
provided signed informed consent for this study that was approved
by the local Research Ethics Committee.
All patients underwent resection of these tumors using 5-
ALA (5-aminolevulinic) fluorescence guidance with an aim of
resecting the entire contrast-enhancing tumor as defined by the
surgical RANO criteria.26 Postoperative imaging within 72 hours
of surgery showed that this was achieved in 39 patients (78%).
Imaging Studies
All patients were imaged within a week prior to surgery on a 3T
Magnetom Trio MR scanner (Siemens Healthcare, Erlangen, Ger-
many), using a standard 8-channel receive head coil and transmis-
sion on the body coil. Conventional anatomical imaging sequences,
diffusion tensor imaging, DSCI, and 1H MR multivoxel spectro-
scopic imaging (CSI) were performed on all patients. The anatomi-
cal sequences included: an axial precontrast T1-weighted sequence
(relaxation time / echo time [TR/TE]: 500/8.6 msec, number of
excitations [NEX]: 1, slice thickness/interslice gap: 4/1 mm, in-
plane resolution: 0.74 mm, field of view [FOV]: 24 3 24 cm, 4
min 22 sec); an axial FLAIR sequence (TR/TE/TI: 7840/95/2500
msec, NEX: 1, slice thickness/interslice gap: 4/1 mm, in-plane
resolution: 0.7 mm, FOV: 22.4 3 16.8 cm, 4 min 28 sec). Diffu-
sion tensor imaging (DTI) was performed with a single-shot SE-
EPI sequence (TR/TE: 8300/98 msec, slice thickness: 2 mm, no
gap, in-plane resolution: 2 mm, 12 directions, 5 b-values: 350/
650/1000/1300/1600 s/mm2, FOV: 19.2 3 19.2 cm, 9 min 26
sec). DSCI was performed (TR/TE: 1500/30 msec, slice thickness:
5 mm, in-plane resolution: 2 mm, FOV 19.2 3 19.2 cm; 90 vol-
umes acquired, 2 min 21 sec) with 9 mL of gadobutrol (Gadovist
1.0 mmol/mL) followed by a 20-mL saline flush given via a power
injector at a rate of 5 mL per second after the tenth volume. Fol-
lowing contrast injection a postcontrast 3D T1-weighted inversion
recovery sequence was performed (MPRAGE; TR/TE/TI: 2300/
2.98/900 msec, NEX: 1, slice thickness: 1 mm, no gap, in-plane
resolution: 1 mm, FOV: 25.6 3 24.1 cm, 9 min 14 sec). To plan the
subsequent spectroscopy, an axial T2-weighted acquisition was per-
formed (TR/TE: 4840/114 msec, NEX: 1, slice thickness/interslice
gap: 4/1 mm, in-plane resolution: 1 mm, FOV: 22 3 16.5 cm, 1
min 33 sec). 2D multivoxel 1H MRS was performed using the semi-
LASER sequence,27 with (NEX: 3) water suppression (TR/TE: 2000/
35 msec, slice thickness: 20 mm, FOV: 16 3 16 cm, 16 3 16 grid
with Hamming acquisition filter, 8 min 6 sec).
Postprocessing of Imaging Data
All data processing was performed offline. The DTI data were
processed using the FDT toolbox in FSL (FMRIB, Oxford, UK).
For each voxel, the eigenvalues (k1, k2, k3) were calculated and
were used to construct the p and q maps using the methodology
and terminology described previously.16
The DSCI data were processed using NordicICE (Nordic-
NeuroLab, Bergen, Norway) and maps of rCBV were generated
following contrast agent leakage correction.
The MRS data were processed using LC Model.28 All spectra
from the selected voxels were assessed visually for artifacts accord-
ing to the criteria described by Kreis.29 The values of the Cramer–
Rao lower bounds indicated by the program were used to evaluate
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the quality and reliability of the 1H spectra and values greater than
20% were discarded. The metabolites were expressed as a ratio to
creatine to avoid the dilutional effects associated with varying
amounts of peritumoral edema30
Regions of Interest (ROIs)
For each patient the contrast-enhanced T1-weighted sequence,
DTI, and DSCI parametric maps were individually coregistered to
the T2-weighted images used to plan the grid for the MRS for that
patient using the FLIRT toolbox in FSL (affine transformation
with 12 degrees of freedom). For the DTI images the p images
(that had improved anatomical details) were coregistered and the
transformation matrix applied to the q images. Coregistered images
were inspected visually by S.J.P. (with 15 years neuroimaging expe-
rience) to ensure good quality of registration by outlining anatomi-
cal structures (eg, ventricles) and assessing the accuracy. The
registered images were discarded and coregistration repeated if
there were errors of registration greater than 2 mm. This allowed
the DTI, perfusion, spectroscopy, and anatomical information to
be in the same imaging space.
For each of the p and q maps, ROIs were drawn around the
visible abnormality on every slice by two reviewers—a neurosur-
geon with 15 years of advanced imaging experience who was
involved in developing the methodology, and a radiologist with 11
years experience, using ImageJ software (National Institutes of
Health, Bethesda, MD). In a random subsample of 15 patients
two trained readers independently drew the ROIs twice at different
timepoints to determine both the inter- and intrarater agreement.
Statistical Analysis
Three regions of interest were determined based on the spectros-
copy grid, as shown in Fig. 1:
1. Invasive: in the DTI-defined invasive region (ie, within the area
of increased p and outside the area of reduced q regions);
2. Noninvasive: in an area outside of the DTI-defined area (ie,
outside the p abnormality) but in an area similar to the inva-
sive ROI according to anatomical imaging (ie, T2-weighted and
contrast-enhanced T1-weighted areas);
3. Normal white matter: in the white matter of the contralateral hemi-
sphere, avoiding any visible pathology (as assessed by S.J.P.).
ROIs were identified where all of the MRS voxels fitted
within the regions described above to avoid the issue of partial vol-
ume effects. The rCBV was calculated for each of the ROIs as a
ratio to normal white matter taken from the contralateral centrum
semiovale. Spectroscopic measures of N-acetylaspartate (NAA),
myo-inositol (Ins), total choline (Cho) including phosphocholine
and glycerylphosphorylcholine, and glutamate1 glutamine (Glx)
were expressed as a ratio to the total creatine (including phospho-
creatine) for each ROI. We felt that it is preferable quantifying
metabolites to total creatine (which varies across the tumor) to the
water resonance due to problems with dilution in regions of edem-
atous brain.31 Similarly, the NAA/Cho ratio was determined for
each ROI. All values are quoted as mean with 95% confidence
interval (CI) unless otherwise stated.
Data were analyzed using IBM SPSS v. 21 (Armonk, NY) and
significance was taken at the P< 0.05 level. Differences between the
three groups were explored with analysis of variance (ANOVA), with
post-hoc analysis using the Tukey-Kramer honestly significant differ-
ence (HSD) test. The receiver operator characteristic (ROC) was cal-
culated for each of the parameters to determine which provided the
best predictor of the DTI-invasive regions. This was performed by
taking the values from 129 ROIs (47 invasive, 40 noninvasive, and
42 normal white matter) and used the binary classification system as
invasive or not invasive (which included both the noninvasive and
normal white matter ROIs) based on the DTI data. The agreement
was quantified using two methods: Dice scores, which are a measure
of the extent of overlap between the ROIs, and the edge Hausdorff
distance32 between the ROIs, which is a measure of the maximal dis-
tance between the edges of the ROIs being compared. As the Haus-
dorff distance can be sensitive to outliers, the 95th percentile of the
distance was used instead. Classification of the pattern of invasion
was made according to previously published criteria.22
Results
DTI Studies
Regions of abnormal p and q from the DTI data could be
identified in all patients. Overall, 34 (68%) had a diffuse
invasive pattern, 12 (24%) had a localized pattern, and 4
(8%) were minimally invasive. Thirty datasets were ran-
domly assigned to two independent raters. There was agree-
ment in 27 cases (90%), providing a Cohen’s kappa statistic
of 0.81, suggesting very good interrater agreement for the
classification of the invasive phenotype. A consensus opinion
was used where there was disagreement.
FIGURE 1: An example of the placement of ROIs. The DTI and
DSCI data were coregistered to the T2-weighted sequence
used to plan the spectroscopy grid (shown in white). The p
abnormality (red line) and q (yellow line) is outlined to identify
the invasive margin. Regions of interest were taken from (a)
the invasive region, (b) the noninvasive region, and (c) contra-
lateral normal brain. Measures of rCBV and MRS were made
from each region.
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Interrater variability of the ROIs showed good agree-
ment between the two raters. There was excellent agreement
for the p regions, with mean Dice scores of 0.86 (SD 0.11)
and the mean 95th centile of the edge Hausdorff distance
was 8.2 mm (SD 4.7 mm). The q region agreement
between the two raters was also good, but was not as robust
as the p region (mean Dice scores 0.76, SD 0.16; mean
95th centile of the edge Hausdorff distance 15.7 mm, SD
9.9 mm). There was excellent intrarater agreement for both
p (mean Dice scores 0.88, SD 0.09; mean 95th centile of
the edge Hausdorff distance 7.0 mm, SD 4.9 mm) and q
ROIs (mean Dice scores 0.85, SD 0.1; mean 95th centile of
the edge Hausdorff distance 8.6 mm, SD 7.3 mm).
Perfusion Imaging
Values of rCBV could be calculated in all 50 patients. The
rCBV was increased in invasive regions (mean 1.64, 95%
CI 1.5–1.78; P< 0.001) compared to the noninvasive
regions (1.14; 95% CI 1.09–1.18) and normal white matter
(1.06, 95% CI 1.02–1.10; P< 0.001). There was no differ-
ence between rCBV values in the noninvasive and normal
white matter regions (P5 0.36).
MRS
An example of the MR spectra in the ROIs is shown in
Fig. 2. The results for the spectroscopy data are summarized
in Fig. 3. Useable spectroscopic data were obtained in 41
patients (82%), dropping to 35 patients (70%) for Glx.
The NAA/Cr was significantly reduced in invasive
regions (0.95, 95% CI 0.85–1.05) compared to either non-
invasive (1.19, 95% CI 1.06–1.31; P5 0.008) or normal
white matter (1.26, 95% CI 1.15–1.36; P< 0.001). There
was no difference between noninvasive and normal white
matter (P5 1.0).
The total choline/creatine (Cho/Cr) ratio was signifi-
cantly increased in the invasive area (0.42, 95% CI 0.38–
0.46) compared to both the noninvasive region (0.35, 95%
CI 0.31–0.38; P5 0.02) and normal white matter (0.35,
95% CI 0.31–0.39; P5 0.019). There was no difference
between these two regions (P5 1.0).
The glutamate1 glutamine to creatine ratio (Glx/Cr)
was significantly increased in the invasive region (1.54, 95%
CI 1.27–1.82) compared to both the noninvasive region
(1.3, 95% CI 1.13–1.47; P 0.028) and to normal white
matter (1.15, 95% CI 0.99–1.31; P5 0.034). There was no
difference between the noninvasive and normal regions
(P5 0.59).
The choline/NAA ratio, a marker of cellular prolifera-
tion,33 was increased in the invasive region (0.54, 95% CI
0.41–0.68) compared to both the noninvasive region (0.37,
95% CI 0.29–0.45; P5 0.032) and the normal white mat-
ter (0.32, 95% CI 0.25–0.39; P5 0.004). The latter two
groups did not differ (P5 0.78)
The myoinositol/creatine (mI/Cr) ratio was not signifi-
cantly different in either the invasive (1.2, 95% CI 0.99–
1.41; P5 0.35) or the noninvasive regions (1.3, 95% CI
1.14–1.46; P5 0.68) compared to the normal white matter
(1.37, 95% CI 1.24–1.5).
FIGURE 2: An example of MR spectra from different ROIs in a
glioblastoma patient. a: The invasive region (in black) com-
pared with the normal brain (blue). The invasive region demon-
strates increased Cho and significantly reduced NAA with
increased Glx. b: The noninvasive region (in black) compared
with the normal brain (red). There is no significant differences
between metabolites in these regions.
FIGURE 3: Percentage change from normal white matter.
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Predicting Invasive Regions
The ROC showed that the rCBV data provided a better
predictor of the DTI-defined invasive regions than the spec-
troscopic measures (data shown in Fig. 4). Using a cutoff
for the rCBV of 1.25 provides a predictor with a sensitivity
and specificity of 82% for identifying invasive tumor.
Discussion
Attempts to study the peritumoral region of GBMs, usually
defined as the peripheral nonenhancing or edematous
region, have shown that there is an increase in total choline
and the Cho/NAA ratio with a reduction in total
NAA.31,34–38 Histological studies suggest that total choline
and Cho/NAA increase with the degree of invasion of sur-
rounding brain.36 These changes are not seen in the peritu-
moral region of noninvasive meningiomas and metastases.31
Similarly, areas of increased perfusion have been found in
the peritumoral region of GBMs.39–41 In this study we were
able to improve the characterization of the peritumoral
region using DTI, and have shown that the DTI-defined
invasive region has a different local environment compared
to either noninvasive or normal contralateral brain using
multimodal MRI. Outlining these invasive regions showed
high interrater agreement, suggesting a robust methodology.
There was an increase in rCBV, Cho/Cr, Cho/NAA, and
Glx/Cr, with a decrease in NAA/Cr in the invasive regions.
The noninvasive regions, although showing similar appear-
ances on conventional imaging to the invasive regions, had
a similar local environment to the normal-appearing brain
from the contralateral hemisphere on multimodal MRI.
In this study we defined the invasive region of the
brain based purely on the DTI. Previous studies have justi-
fied this and shown that image-guided biopsies of the DTI-
defined invasive region can indeed identify invasive tumor
with a high degree of accuracy.8,19 A number of studies
have now shown that these DTI-defined invasive regions
also predict the site of tumor progression as defined by the
site where new contrast enhancement develops.19,21,22 Our
imaging methods are only sensitive enough to detect tumor
cells outside of the main contrast-enhancing tumor when
they are present in large numbers. As alluded to previously,
it is clear that the noninvasive region will still contain
tumor cells. As virtually all tumors will recur adjacent to the
resection cavity,2–5 it has been suggested that detecting the
site of likely tumor progression (ie, the area with the largest
number of tumor cells outside the target of surgical resec-
tion) is more important than identifying the true extent of
invasion.5
These findings provide information on the local envi-
ronment of the invasive region that correlates with our
FIGURE 4: The ROC curves for the imaging parameters performance at differentiating invasive region vs. noninvasive (which
includes both the noninvasive and normal ROIs). The curve for rCBV suggests that this may be the best discriminator.
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understanding of the multiple processes that occur during
invasion. As mentioned previously, the invasive cells have a
different phenotype, in that they are less proliferative than
enhancing tumor. The Cho/NAA ratio has been shown in
some studies to correlate well with the proliferation of
tumor cells:33,42 although Cho/NAA increased in the inva-
sive regions in the current study, it was still much lower
than in other studies that looked at the enhancing tumor.43
Others have found choline content to correlate more closely
with cell density than proliferation index.44,45 As the cell
density increases, angiogenesis is stimulated by the resultant
hypoxia, resulting in increased rCBV. The increase in rCBV
appears to be the best measure to identify these invasive
regions and has been suggested as a marker that precedes
the development of contrast-enhanced tumor.41 The release
of enzymes to degrade the extracellular matrix is accompa-
nied by glutamate release in excitotoxic concentrations.10,46
This is consistent with the increase in Glx/Cr in these inva-
sive areas seen in our study and reported by other groups
looking at GBMs.47–49 The net effect of these processes is
the loss of neurons (measured by decrease in NAA).
In our study we failed to identify a significant change
in myoinositol in the invasive region compared to normal
brain. Myoinositol is thought to be involved with astrocytic
integrity and regulation of brain osmosis.50 Astrocytic pro-
liferation is associated with an increase in myoinositol and
has been reported in the peritumoral region.31,47 As the
grade of tumor increases, however, myoinositol levels
decrease, so that in GBMs they are similar to normal
brain.51,52 Our data certainly show a nonsignificant trend of
reduced myoinositol in DTI-defined invasive regions where
previous histological studies have shown extensive invasion
with high glioma cells8 replacing other normal cell popula-
tions (including astrocytes).
The local environment of a tumor has a major influ-
ence on how that tumor will behave and respond to ther-
apy.53 Most imaging studies that aim to predict prognosis
or response to therapy have derived measures from the
contrast-enhancing tumor alone. Recent publications suggest
that studying the nonenhancing component of the tumor
also provides prognostic information.54 Advances in modern
neurosurgery now mean that complete resection of the
contrast-enhancing tumor is achieved more often; in our
series, a complete resection of the contrast-enhancing tumor
was achieved in 78% of cases. The result is that nonenhanc-
ing tumor margin will be the site of progressive tumor.
Studying these regions may be more relevant to prognostica-
tion and response to therapies performed after surgical
treatments.
One major limitation of our work is the difference in
resolution, slice thickness, and gaps between the anatomical
imaging, DTI imaging (2 3 2 3 2 mm voxel size providing
whole brain coverage), DSC imaging (2 3 2 3 5 mm voxel
size providing whole brain coverage), and our single-slice
multivoxel spectroscopic imaging (10 3 10 3 20 mm voxel
size). This will lead to issues with the coregistration and
lead to partial volume errors. The difference in voxel size is
particularly critical for the MRS data and means that the
spectral pattern will be dependent on the relative amount of
tumor to normal brain in these invasive regions. But these
limitations will be the same for each of the three ROIs we
compared for each patient. Our findings would suggest that
in the DTI-defined invasive regions there is a high propor-
tion of tumor cells, whereas in noninvasive regions there is
more normal brain. Other groups have published their expe-
rience of 3D spectroscopy—but even then only managed a
voxel size of 10 3 10 3 10 mm.55 They described changes
in NAA and Cho in normal-appearing white matter sur-
rounding gliomas. This study used a longer echo time (70
msec) and as a result was not able to analyze metabolites
with smaller concentrations (eg, myoinositol and glutama-
te1 glutamine). Newer sequences providing 3D short echo
spectroscopy have been developed and shown to be repro-
ducible56 but still suffer from poor resolution compared to
DTI and DSCI and long acquisition times that make it dif-
ficult to use for multimodal imaging in this population. It
is likely, however, that these methods will be utilized in the
future.
In conclusion, by using DTI to define the limits of
invasion we see changes in the local environment in invasive
regions that are not seen in noninvasive brain and which fit
with our understanding of glioma invasion.
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